Innovent Biologics, Inc. (FRA:6IB)

Innovent Biologics Statistics

Total Valuation

FRA:6IB has a market cap or net worth of EUR 16.95 billion. The enterprise value is 16.20 billion.

Market Cap	16.95B
Enterprise Value	16.20B

Important Dates

The next estimated earnings date is Wednesday, March 25, 2026.

Earnings Date	Mar 25, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	1.72B
Shares Outstanding	n/a
Shares Change (YoY)	+3.74%
Shares Change (QoQ)	+3.84%
Owned by Insiders (%)	6.45%
Owned by Institutions (%)	36.11%
Float	1.60B

Valuation Ratios

The trailing PE ratio is 125.92 and the forward PE ratio is 55.76.

PE Ratio	125.92
Forward PE	55.76
PS Ratio	12.48
PB Ratio	9.89
P/TBV Ratio	10.94
P/FCF Ratio	98.49
P/OCF Ratio	78.49
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 106.05, with an EV/FCF ratio of 94.16.

EV / Earnings	120.39
EV / Sales	11.74
EV / EBITDA	106.05
EV / EBIT	155.05
EV / FCF	94.16

Financial Position

The company has a current ratio of 2.61, with a Debt / Equity ratio of 0.23.

Current Ratio	2.61
Quick Ratio	2.25
Debt / Equity	0.23
Debt / EBITDA	2.54
Debt / FCF	2.33
Interest Coverage	10.22

Financial Efficiency

Return on equity (ROE) is 8.43% and return on invested capital (ROIC) is 3.46%.

Return on Equity (ROE)	8.43%
Return on Assets (ROA)	2.65%
Return on Invested Capital (ROIC)	3.46%
Return on Capital Employed (ROCE)	5.00%
Revenue Per Employee	219,341
Profits Per Employee	21,743
Employee Count	5,659
Asset Turnover	0.52
Inventory Turnover	2.94

Taxes

In the past 12 months, FRA:6IB has paid 9.36 million in taxes.

Income Tax	9.36M
Effective Tax Rate	6.50%

Stock Price Statistics

The stock price has increased by +134.30% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+134.30%
50-Day Moving Average	9.53
200-Day Moving Average	8.63
Relative Strength Index (RSI)	58.44
Average Volume (20 Days)	390

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:6IB had revenue of EUR 1.36 billion and earned 134.59 million in profits. Earnings per share was 0.08.

Revenue	1.36B
Gross Profit	1.04B
Operating Income	110.46M
Pretax Income	143.95M
Net Income	134.59M
EBITDA	154.81M
EBIT	110.46M
Earnings Per Share (EPS)	0.08

Balance Sheet

The company has 1.13 billion in cash and 401.67 million in debt, with a net cash position of 732.28 million.

Cash & Cash Equivalents	1.13B
Total Debt	401.67M
Net Cash	732.28M
Net Cash Per Share	n/a
Equity (Book Value)	1.71B
Book Value Per Share	1.04
Working Capital	960.45M

Cash Flow

In the last 12 months, operating cash flow was 215.90 million and capital expenditures -43.83 million, giving a free cash flow of 172.08 million.

Operating Cash Flow	215.90M
Capital Expenditures	-43.83M
Free Cash Flow	172.08M
FCF Per Share	n/a

Margins

Gross margin is 76.62%, with operating and profit margins of 8.14% and 9.91%.

Gross Margin	76.62%
Operating Margin	8.14%
Pretax Margin	10.60%
Profit Margin	9.91%
EBITDA Margin	11.40%
EBIT Margin	8.14%
FCF Margin	12.67%

Dividends & Yields

FRA:6IB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.74%
Shareholder Yield	-3.74%
Earnings Yield	0.79%
FCF Yield	1.02%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:6IB has an Altman Z-Score of 4.57 and a Piotroski F-Score of 8.

Altman Z-Score	4.57
Piotroski F-Score	8